• World News
  • Politics
  • Stock
  • Investing
  • Editor’s Pick
Time And Sales Reporter
Editor's PickInvesting

The Crypto Industry Should Not Seek to Punish Its Competition

by March 14, 2025
March 14, 2025

Norbert Michel

Credit card

I’ve written several articles on the punitive Credit Card Competition Act and why its policies are misguided. It’s based on a myth that the “big credit card companies” have some kind of monopoly, duopoly, or anticompetitive power.

But it is a myth, and implementing routing requirements or price controls (indirectly or directly) will not promote competition. It will harm competition. Those policies will not promote innovation or expand consumer choice. They will hinder innovation and shrink consumer choice.

Now, in a story that is typical of how Washington works, two special interest groups have joined forces to support the punitive Credit Card Competition Act.

The two groups, the Merchants Payments Coalition (MPC) and the Payment Choice Coalition (PCC) have just announced that they are “each joining the other’s group to promote their shared goals of enhancing innovation, competition, and choice in U.S. payments.”

The pitch sounds lovely, but there’s a special interest twist. Members of the PCC include Coinbase, Circle, and the Blockchain Association.

So, that’s how far the crypto industry has come. They started out just pushing for a new regulatory framework, so that crypto and stablecoins could compete with other payments technologies. And now they’re actively pushing for the Credit Card Competition Act, legislation that would unambiguously harm credit card companies and other payments firms. 

Actively seeking rules and regulations that would harm your competition has practically become a rite of passage in Washington, so it’s unsurprising to see crypto firms supporting these policies. But it’s still incredibly disappointing.

It’s also incredibly shortsighted. Giving more power to regulators to dictate terms in the payments sector will not end well for crypto firms. Eventually, regulators will restrict them at the expense of other groups. 

previous post
Senate to take up Trump spending bill as clock ticks down to government shutdown
next post
MedPAC Identifies Medicare Advantage Pricing Errors, Savings Opportunities

Related Posts

Trump’s Argentina beef import plan will harm U.S....

October 24, 2025

Travis Kelce part of investor group aiming to...

October 24, 2025

Top 4 Canadian Biotech Stocks of 2025

October 24, 2025

Queensland Uranium and Rare Earth Acquisition Completed

October 24, 2025

Quimbaya Gold Announces C$10 Million Bought Deal Financing

October 24, 2025

Sun Summit Minerals to Present at the 51st...

October 24, 2025







    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.




    Recent Posts

    • Trump’s Argentina beef import plan will harm U.S. ranchers, industry warns

      October 24, 2025
    • Travis Kelce part of investor group aiming to revive struggling Six Flags

      October 24, 2025
    • Jack Smith pushes for public testimony to confront ‘mischaracterizations’ of Trump probes

      October 24, 2025
    • Trump ‘not interested’ in de-escalation with ‘unhinged’ leader of Colombia, White House says

      October 24, 2025
    • Mayor Eric Adams endorses Andrew Cuomo as his successor as Zohran Mamdani maintains lead in NYC race

      October 24, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 timeandsalesreporter.com | All Rights Reserved

    Time And Sales Reporter
    • World News
    • Politics
    • Stock
    • Investing
    • Editor’s Pick

    Read alsox

    Friday Feature: PASS Network and PASS Pod

    February 14, 2025

    Pass-Through Deduction Wins Worst Tax Expenditure

    April 7, 2025

    Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy...

    May 15, 2025